HbA1c testing in the diagnosis of diabetes mellitus
Parsons J, Vogan A, Morona J, Schubert C, Merlin T
Record ID 32015000102
English
Original Title:
Application 1267
Authors' recommendations:
The studies that were included in the assessment of HbA1c test accuracy, with retinopathy as the reference standard, were of poor quality and dated. However, there was little difference between the discriminatory power of FPG, OGTT and HbA1c to predict retinopathy, despite there being considerable discordance when the tests were directly compared to one another. In terms of the cost impact of introducing the test, the estimates ranged widely between cost savings of $6 million to net costs of $50 million, annually. Given the multiple uncertainties in the estimated population eligible for testing and other testing parameters, the financial implications to the MBS could not be confidently estimated.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/C566B7E2A2C1CBE9CA25801000123BAD/$File/1267-FinalContractedAssessmentReport-accessible.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Diabetes Mellitus
- Diagnosis, Differential
- Blood Glucose
- Reference Values
- Early Diagnosis
- Sensitivity and Specificity
- Predictive Value of Tests
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.